Something has shifted
For decades, pharmaceutical manufacturing in the United States was concentrated in a handful of states. New Jersey. North Carolina. Pennsylvania. Texas wasn't in that conversation.
That's changing fast.
In the last two years, Texas - and Houston specifically - has emerged as one of the most active destinations for pharmaceutical manufacturing investment in the country. The projects are large, the timelines are real, and the construction activity is just getting started.
The headline number
Major pharmaceutical companies have pledged more than $370 billion in U.S. manufacturing investment over the next five years - a figure described by a senior leader at DPR Construction, one of the largest life sciences AEC firms in the country, as unprecedented in over 35 years of industry experience. Houston
Texas is capturing a meaningful share of that investment.
What's landing in Houston
Eli Lilly announced a $6.5 billion investment to build a 236-acre pharmaceutical manufacturing facility at Generation Park in Houston - the first major pharmaceutical manufacturing facility investment in Texas history. repulsestudio
The facility will focus on manufacturing small molecule medicines across cardiometabolic health, oncology, immunology, and neuroscience - and is expected to be operational within five years. The project is expected to create more than 615 full-time jobs and over 4,000 regional construction jobs during the build. GZ Module Pagesrepulsestudio
That's one project. It won't be the last.
Why Texas, why now
Several factors are converging at the same time.
Texas has long had the infrastructure advantages - business-friendly regulation, low taxes, and a large skilled labor pool. What it lacked was the biotech ecosystem and workforce pipeline specific to pharmaceutical manufacturing.
That gap is closing. San Jacinto College and Generation Park launched the Center for Biotechnology - the only National Institute for Bioprocessing Research and Training licensed training provider in the southern United States - built specifically to supply the workforce these new facilities will need. repulsestudio
The ecosystem is being built alongside the facilities, not after them.
What this means for life sciences AEC
New GMP facilities don't just appear. They go through years of design, planning, permitting, regulatory review, and construction before a single batch of product is manufactured inside them.
Every one of those phases requires documentation. Floor plans need to be reviewed and approved. Compliance logic needs to be communicated to stakeholders who aren't engineers. Capital partners need to understand what they're funding. Regulatory reviewers need to see how the facility functions before it's built.
The volume of GMP facility work coming to Texas over the next five years is going to create demand for every service in the life sciences AEC supply chain - including visualization.
Where Repulse Studio fits
Repulse Studio was built specifically for this moment. GMP facility visualization for life sciences AEC firms and pharmaceutical manufacturers - delivered from Texas, for the projects being built here.
The story of Texas becoming a pharmaceutical hub is still being written. The firms that document it clearly will have an advantage at every stage of the process.